Fusion polypeptides
    6.
    发明授权
    Fusion polypeptides 失效
    融合多肽

    公开(公告)号:US06423512B1

    公开(公告)日:2002-07-23

    申请号:US08897956

    申请日:1997-07-21

    IPC分类号: A61K3817

    摘要: Fusion polypeptides and salts thereof comprising at least one IgE-binding domain fused to at least one human serum albumin component, optionally via a peptide linker, and in particular, dimeric fusion polypeptides comprising HSA protein fused, at each of its amino and carboxy termini, to an extracellular domain of the &agr;-chain of the human high affinity receptor for IgE (Fc&egr;RI&agr;); process for the preparation thereof, functionally equivalent polypeptides which are intermediates in their preparation, and polynucleotide and oligonucleotide intermediates and vectors therefor. They are indicated for use in the prevention and/or treatment of IgE-mediated allergic diseases and related disorders such as atopic dermatitis, atopic asthma and chronic urticaria.

    摘要翻译: 融合多肽及其盐包含与至少一种人血清白蛋白组分融合的至少一个IgE结合结构域,任选经由肽接头,特别是包含在其氨基和羧基末端各自融合的HSA蛋白的二聚融合多肽, 到人IgE(FcepsiRIalpha)的人高亲和力受体的α链的细胞外结构域; 其制备方法,作为其制备中的中间体的功能等同多肽,以及多核苷酸和寡核苷酸中间体及其载体。 它们被用于预防和/或治疗IgE介导的过敏性疾病和相关疾病如特应性皮炎,特应性哮喘和慢性荨麻疹。